SCHEDULE 13G/A: Wasatch Advisors LP Discloses 5.2% Passive Stake in Sangamo Therapeutics

Wasatch Advisors LP, an investment adviser, has filed an amended Schedule 13G, reporting a passive beneficial ownership of 5.2% in Sangamo Therapeutics, Inc. as of March 31, 2025.

Summary

• Wasatch Advisors LP, a Delaware-based investment adviser, has filed an Amendment No. 8 to Schedule 13G regarding its ownership in Sangamo Therapeutics, Inc.
• As of March 31, 2025, Wasatch Advisors LP beneficially owns an aggregate of 11,630,671 shares of Sangamo Therapeutics' Common Stock.
• This ownership represents 5.2% of the total class of securities.
• Wasatch Advisors LP holds sole voting power over 10,847,230 shares and sole dispositive power over 11,630,671 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Sangamo Therapeutics, Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of ownership, indicating a neutral sentiment as it does not contain performance data or forward-looking statements from the issuer.

Positives

• The disclosure of a significant passive stake by an institutional investment adviser like Wasatch Advisors LP can be viewed as a vote of confidence in Sangamo Therapeutics, Inc.

Industry Context

This filing is a routine disclosure by an institutional investor, common in the biotechnology and pharmaceutical sectors where investment firms frequently take passive stakes in publicly traded companies. It reflects an investment position rather than operational news from Sangamo Therapeutics itself.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, which can influence investor perception.

Key Dates

Keywords

Sangamo Therapeutics, Wasatch Advisors LP, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, SEC Filing